Medicine Press release

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose.
More info..

TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd., a leading global manufacturer of precious metal materials, will exhibit its Visi Fine(R) Series, a lineup of highly radiopaque precious metal materials and other precious metal-based materials for medical device components, at MD&M West 2026, to be held February 3-5, 2026, at the Anaheim Convention Center in Anaheim, California.
More info..

TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd., a leading global manufacturer of precious metal materials, will exhibit its Visi Fine(R) Series, a lineup of highly radiopaque precious metal materials and other precious metal-based materials for medical device components, at MD&M West 2026, to be held February 3-5, 2026, at the Anaheim Convention Center in Anaheim, California.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been listed in the 2026 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc.
More info..

Fujitsu today announced that its project with Social Medical Corporation Genshukai in Iki City, Nagasaki Prefecture, aimed at promoting sustainable hospital management through AI-driven profitability improvement and advanced management, has been selected as one of the advanced solutions in the MINDS program hosted by the AI Global Alliance of the World Economic Forum
More info..

Taletrectinib is a highly selective, next-generation oral treatment currently approved for patients living with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the U.S., China, and Japan.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of LEQEMBI(R) (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, has been accepted by the National Medical Products Administration (NMPA) in China.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of LEQEMBI(R) (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, has been accepted by the National Medical Products Administration (NMPA) in China.
More info..

Kirin Holdings Company, Limited and Fujitsu Limited have jointly conducted research on food functionality simulation with the goal of creating new functionalities in food.
More info..